Forte Biosciences Inc expected to post a loss of 32cents a share - Earnings Preview

Forte Biosciences

18/03/2022 21:10

* Forte Biosciences Inc  FBRX.OQ   FBRX.O  is expected
to show no
change in quarterly revenue when it reports  results on March 22
(estimated). 
    * ​Refinitiv's mean analyst estimate for Forte Biosciences
Inc is
for a loss of 32 cents per share. For the same quarter last
year, the company reported a loss of 37 cents per share.
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Forte
Biosciences
Inc is $3.5​, above​ its last closing price of $1.46. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.36       -0.36      -0.54     Missed  -47.9
 Jun. 30 2021  -0.44       -0.43      -0.43     Met     0.6
 Mar. 31 2021  -0.45       -0.52      -0.36     Beat    31.4​
 Dec. 31 2020              -0.57      -0.37     Beat    35.5
 ​​Sep.        -0.54       -0.54      -0.45     Beat    16.7
 30 2020                                                
 Jun. 30 2020  -0.19       -0.19      -9.52     Missed  -4,910
                                                        .5​
 Mar. 31 2020              -6.60      -6.45     Beat    2.3
 Dec. 31 2019  -8.58       -8.55      -7.50     Beat    12.3
 This summary was machine generated March 18 at 21:10 GMT.  All
figures in US dollars  unless otherwise stated